Cervical carcinoma high-expressed long non-coding RNA 1 may promote growth of colon adenocarcinoma through interleukin-17A

Abstract

Cervical carcinoma high-expressed long non-coding RNA 1 (CCHE1) has been demonstrated to promote several different types of cancer; however, the involvement of CCHE1 in other types of cancer remains unknown. In the present study, the expression levels of CCHE1 and interleukin (IL)-17A were increased in the plasma of patients with metastatic and non-metastatic colon adenocarcinoma (MC and NMC, respectively) compared with the healthy controls. There was no significant difference in the plasma expression levels of CCHE1 and IL-17A in patients with MC compared with patients with NMC. The plasma expression levels of CCHE1 and IL-17A were positively associated with the primary tumor diameter. A significant correlation as demonstrated between the serum levels of CCHE1 and IL-17A in patients with colon adenocarcinoma, but not in the healthy controls. CCHE1 and IL-17A overexpression promoted colon adenocarcinoma cell proliferation. Transfection of small interfering RNA against IL-17A partially reversed the effects of CCHE1 overexpression on cancer cell proliferation. Upregulation of IL-17A was observed after CCHE1 overexpression, while IL-17A overexpression did not significantly change the expression level of CCHE1. Therefore, CCHE1 may promote growth of colon adenocarcinoma through interactions with IL-17A.

Keywords: cervical carcinoma high- expressed long non-coding RNA 1; colon adenocarcinoma; interleukin-17A; metastasis; tumor growth.

Figure 1.

CCHE1 and IL-17A expression levels are upregulated in patients with colon adenocarcinoma, but are not affected by the presence of distant tumor metastases. Plasma levels of (A) CCHE1 and (B) IL-17A mRNA were significantly increased in patients with MC and NMC, while no significant differences in plasma levels of CCHE1 and IL-17A mRNA were found between MC and NMC groups. *P<0.05. MC, metastatic colon adenocarcinoma; NMC, non-metastatic colon adenocarcinoma; CCHE1, cervical carcinoma high-expressed long non-coding RNA 1; IL-17A, interleukin-17A.

Figure 2.

Plasma levels of CCHE1 and IL-17A increase concurrently with primary tumor diameter. Plasma levels of (A) CCHE1 and (B) IL-17A increased with an increase in the primary tumor diameter. *P<0.05. CCHE1, cervical carcinoma high-expressed long non-coding RNA 1; IL-17A, interleukin-17A.

Figure 3.

Plasma levels of CCHE1 and IL-17A are positively correlated in patients with colon adenocarcinoma, but not in healthy controls. Pearson's correlation coefficient analysis showed that plasma levels of CCHE1 and IL-17A were positively correlated in (A) patients with colon adenocarcinoma (B) but not in healthy controls. CCHE1, cervical carcinoma high-expressed long non-coding RNA 1; IL-17A, interleukin-17A.

Figure 4.

Downregulation of plasma cervical carcinoma high-expressed long non-coding RNA 1 distinguishes early stage patients with colon adenocarcinoma from healthy controls. Receiver operating characteristic curve analysis showed that the area under the curve was 0.8745, with standard error of 0.05599 and 95% confidence interval of 0.7378–0.9573.

Figure 5.

CCHE1 overexpression leads to an increase in IL-17A expression in the colon adenocarcinoma cell lines Hs 698.T and SNU-C1. (A) CCHE1 overexpression significantly upregulated expression of IL-17A in both Hs 698.T and SNU-C1 colon adenocarcinoma cell lines. (B) IL-17A overexpression did not significantly alter the expression of CCHE1 in Hs 698.T or SNU-C1 colon adenocarcinoma cell lines. *P<0.05. C, control; NC, negative control; CCHE1, cervical carcinoma high-expressed long non-coding RNA 1; IL-17A, interleukin-17A.

Figure 6.

CCHE1 overexpression promotes colon adenocarcinoma cell proliferation through IL-17A. (A) CCHE1 and IL-17A overexpression were achieved. (B) CCHE1 and IL-17A overexpression significantly promoted proliferation of Hs 698.T or SNU-C1 colon adenocarcinoma cell lines. IL-17A small interfering RNA silencing inhibited cell proliferation and attenuated the enhancing effects of CCHE1 overexpression on cell proliferation. *P<0.05. CCHE1, cervical carcinoma high-expressed long non-coding RNA 1; IL-17A, interleukin-17A; siRNA, small interfering RNA; C, control; NC, negative control.